Featured Research

from universities, journals, and other organizations

Transplanted Fatty Livers Associated With Worse Prognosis For Patients With HCV

Date:
January 13, 2009
Source:
Wiley-Blackwell
Summary:
A new study suggests that patients with hepatitis C who need a liver transplant should not receive an organ with high levels of fatty deposits (hepatic steatosis). Hepatitis C recurrence was more frequent and earlier among those transplanted with such livers.

A new study suggests that patients with hepatitis C (HCV) who need a liver transplant should not receive an organ with high levels of fatty deposits (a.k.a. hepatic steatosis). HCV recurrence was more frequent and earlier among those transplanted with such livers. 

Related Articles


Recently, reports have revealed that survival rates among HCV-infected liver transplant recipients are decreasing. This is particularly troubling because HCV is the most common indication for liver transplantation in Western countries. In these places, the donor population is more likely to be overweight, and therefore more likely to have fatty livers. These organs are highly susceptible to cold or warm ischemia injury, leading researchers to hypothesize that liver steatosis may be affecting the outcomes for transplant recipients.

Researchers, led by Javier Briceño and Ruben Ciria of Cordoba, Spain, sought to determine the influence of donor liver steatosis on outcomes for HCV patients who received them. They included 120 patients who underwent liver transplantation as a result of HCV-cirrhosis between 1995 and 2005. Donor steatosis was categorized as absent (0-10 percent), mild (10-30 percent), moderate (30-60 percent) or severe (greater than 60 percent).

“Our results show a direct relationship between marginal donor, graft steatosis and a more frequent, severe and earlier viral recurrence after orthotopic liver transplantation for HCV-related cirrhosis,” the authors report. Patient survival was significantly worse when graft steatosis was 30 percent or more.

Survival of the graft was inversely proportional to donor liver steatosis. After three years, graft survival was 72 percent for transplant recipients whose donor livers had no steatosis, 58 percent for mild, 43 percent for moderate and 42 percent for severe. The most profound decline in graft survival occurred when donor livers contained greater than 30 percent steatosis and were subjected to more than 12 hours of cold ischemic time.

The authors compared their results to outcomes of liver transplantations in individuals with alcohol-induced cirrhosis, as opposed to HCV. They found that donor steatosis greater than 30 percent did not reduce graft survival in these non-HCV patients.

“Further multicenter studies and a global consensus may be necessary to finally assess if the use of expanded criteria grafts is safe into HCV-positive recipients, as well as if nowadays the organ allocation system should need a change for this cohort of patients,” they conclude.

An accompanying editorial by Mitchell Shiffman and Nevin Yilmaz of Virginia Commonwealth University Medical Center raises concerns about the study’s conclusions. It points out that all patients did not undergo liver biopsies at specified time intervals, and there was not enough data on the patients with alcohol-induced cirrhosis to be sure that the populations were comparable.

Still, they were intrigued by the observation that the combination of donor graft steatosis and a prolongation in cold ischemic was associated with severe reperfusion injury.

“We strongly suggest that cold ischemia time should be limited when the donor graft contains greater than 30 percent steatosis and such grafts should only be utilized with caution for patients with chronic HCV,” they conclude.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal References:

  1. Briceño, Javier; Ciria, Ruben; Pleguezuelo, Maria; de la Mata, Manuel; Muntané, Jordi; Naranjo, Alvaro; Sanchez-Hidalgo, Juan Manuel; Marchal, Trinidad; Rufian, Sebastian; Lopez-Cillero, Pedro. Impact of Donor Graft Steatosis on Overall Outcome and Viral Recurrence after Liver Transplantation for HCV-Cirrhosis. Liver Transplantation, January 2009
  2. Shiffman, Mitchell; Yilmaz, Nevin. Impact of the Donor Liver with Steatosis in Patients with HCV. Not so Fast. Liver Transplantation, January 2009

Cite This Page:

Wiley-Blackwell. "Transplanted Fatty Livers Associated With Worse Prognosis For Patients With HCV." ScienceDaily. ScienceDaily, 13 January 2009. <www.sciencedaily.com/releases/2009/01/090113130558.htm>.
Wiley-Blackwell. (2009, January 13). Transplanted Fatty Livers Associated With Worse Prognosis For Patients With HCV. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2009/01/090113130558.htm
Wiley-Blackwell. "Transplanted Fatty Livers Associated With Worse Prognosis For Patients With HCV." ScienceDaily. www.sciencedaily.com/releases/2009/01/090113130558.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins